Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX23.989,13+1,01 %

Gold3.335,740,00 %

Öl (Brent)69,62+1,94 %

Dow Jones44.396,02-0,36 %

US Tech 10022.685,81-0,17 %

EUR/USD1,17425+0,28 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Teva Pharmaceutical Industries Aktie

Aktie

ISIN: IL0006290147 WKN: 906517 SYM: TEVJF Land Flagge IL

Israel

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

17,455

USD

+12,03 %

+1,875 USD

Letzter Kurs 16.06.25 Nasdaq OTC

Teva Pharmaceutical Industries Aktie kaufen

BEI SMARTBROKER+ HANDELN

Handeln über unsere
Partner-Broker

Brokerize

Neueste Nachrichten

Teva Releases Q2 2025 Aide Memoire 26.06.25 · globenewswire · Teva Pharmaceutical Industries
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 25.06.25 · globenewswire · Teva Pharmaceutical Industries
Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY (fremanezumab) für die Prävention chronischer und episodischer Migräne 24.06.25 · globenewswire · Teva Pharmaceutical Industries
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY (fremanezumab) for the Prevention of Chronic and Episodic Migraine 23.06.25 · globenewswire · Teva Pharmaceutical Industries
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology 16.06.25 · globenewswire · Teva Pharmaceutical Industries
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer 03.06.25 · globenewswire · Teva Pharmaceutical Industries
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement 03.06.25 · globenewswire · Teva Pharmaceutical Industries
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 31.05.25 · globenewswire · Teva Pharmaceutical Industries
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TE 31.05.25 · globenewswire · Teva Pharmaceutical Industries
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day 29.05.25 · globenewswire · Teva Pharmaceutical Industries
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA 27.05.25 · globenewswire · Teva Pharmaceutical Industries
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June 27.05.25 · globenewswire · Teva Pharmaceutical Industries

1
2
…
3

Meistgelesen

30 Tage
12 Monate

Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit ... 172 Leser
Teva Releases Q2 2025 Aide Memoire 168 Leser
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY ... 152 Leser
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July ... 132 Leser
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy ... 120 Leser

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare ... 224 Leser
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class ... 220 Leser
Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S. 172 Leser
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with ... 172 Leser
Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit ... 172 Leser
Teva Releases Q2 2025 Aide Memoire 168 Leser
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; ... 160 Leser
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer 156 Leser
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 ... 156 Leser
Teva Releases Q1 2025 Aide Memoire 152 Leser